Kalvista Pharmaceuticals. has filed a patent for an on-demand treatment of bradykinin-mediated angioedema using an orally administered plasma kallikrein inhibitor in a patient-friendly oral dosage form. This innovation aims to provide easier treatment options for patients who have difficulty swallowing tablets. GlobalData’s report on Kalvista Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Kalvista Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kalvista Pharmaceuticals, Bio-active prosthesis coating was a key innovation area identified from patents. Kalvista Pharmaceuticals's grant share as of January 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of bradykinin-mediated angioedema with oral plasma kallikrein inhibitor

Source: United States Patent and Trademark Office (USPTO). Credit: Kalvista Pharmaceuticals Inc

A recent patent application (Publication Number: US20230381162A1) discloses a method for treating bradykinin-mediated angioedema on-demand. The method involves orally administering a compound of Formula A, or a pharmaceutically acceptable salt and/or solvate thereof, to a patient in need of treatment. The compound is administered in various oral dosage forms, including chewable tablets, soft gels, mini-tablets, powders, granules, solutions, emulsions, suspensions, syrups, dispersible tablets, or orodispersible tablets. The method specifically targets bradykinin-mediated angioedema, which can be hereditary angioedema (HAE) or non-hereditary angioedema caused by factors such as environmental triggers, hormonal changes, or drug-induced reactions.

Furthermore, the method outlines specific scenarios for administering the compound of Formula A on-demand, such as during the prodromal phase of an angioedema attack or when symptoms of an acute attack are recognized. The treatment aims to shorten the duration of the attack, prevent it from progressing to the swelling stage, or prophylactically reduce the likelihood of an attack. The compound can also be administered in anticipation of triggers like physical trauma, stress, or specific medical procedures. The patent application details the oral dosage forms and specifications for disintegration and dissolution rates to ensure effective delivery of the compound for treating bradykinin-mediated angioedema.

To know more about GlobalData’s detailed insights on Kalvista Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies